Work

A Phase 1 Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination with Etoposide As Preparative Therapy for Autologous Stem Cell Transplant in Acute Myeloid Leukemia

Year: 2014

Type: article

Abstract: Busulfan (BU) and etoposide (VP) have been employed as preparative therapy for autologous stem cell transplantation (autoSCT) in adults with acute myeloid leukemia (AML) for over 20 years. Toxicity and safety significantly improved with the transition from oral to intravenous (IV) BU and the use of pharmacokinetic (PK)-based dosing. In an attempt to enhance outcomes following autoSCT, we designed a Phase I study with the following objectives: 1) to determine the maximum tolerated dose (MTD) of targeted, dose-escalated IV BU in combination with VP- 60mg/kg and 2) to achieve BU levels within +/- 10% of goal in >80% of patients (pts) after dose-adjustment (DA).

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2013.12.167